The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: Cellular mechanisms and clinical implications

Current HIV/AIDS Reports

Volumn 4, Issue 3, 2007, Pages 126-134

  Noor, Mustafa A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; GLUCOSE; INSULIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ADIPOCYTE; BODY FAT DISTRIBUTION; CELL FUNCTION; CHRONIC DISEASE; CHRONIC INFLAMMATION; CIRCULATION; CLINICAL STUDY; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG BLOOD LEVEL; DRUG MECHANISM; DYSLIPIDEMIA; FAT INTAKE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPID STORAGE; LIPOATROPHY; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PHENOTYPE; PREVALENCE; PROTEIN FOLDING; REVIEW; STRESS; TREATMENT OUTCOME; TREATMENT RESPONSE; WAIST HIP RATIO;

ADIPOSE TISSUE; GLUCOSE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LIVER;

EID: 34848844047     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-007-0019-4     Document Type: Review

References (84)

1. Grinspoon SK: Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med 2005, 118(Suppl 2):23S-28S.
2. Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-58.
3. Grunfeld C, Tien P: Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome. Clin Infect Dis 2003, 37(Suppl 2):S43-46.
4. Grundy SM, Brewer HB, Jr, Cleeman JI, et al.: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004, 109:433-438.
5. Friis-Moller N, Weber R, Reiss P, et al.: Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003, 17:1179-1193.
6. Mulligan K, Parker RA, Komarow L, et al.: Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr 2006, 41:590-597.
7. Safrin S, Grunfeld C: Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999, 13:2493-2505.
8. Mallon PW, Miller J, Cooper DA, Carr A: Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003, 17:971-979.
9. Galli M, Cozzi-Lepri A, Ridolfo AL, et al.: Triglyceride level predicts lipoatrophy in patients receiving antiretroviral therapy. Paper presented at the 10th European AIDS Conference. Dublin, Ireland; November 17-20, 2005.
10. Noor M, Dezii C, McLaren C, et al.: Baseline triglyceride levels predict development of lipoatrophy in patients treated with stavudine extended-release/prolonged-release capsules or stavudine immediate-release. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; February 8-11, 2004.
11. Lee GA, Rao MN, Grunfeld C: The effects of HIV protease inhibitors on carbohydrate and lipid metabolism. Curr Infect Dis Rep 2004, 6:471-482.
12. Hommes MJ, Romijn JA, Endert E, et al.: Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 1991, 40:651-656.
13. Brown TT, Cole SR, Li X, et al.: Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study. Arch Intern Med 2005, 165:1179-1184.
14. Mulligan K, Grunfeld C, Tai VW, et al.: Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000, 23:35-43.
15. Noor MA, Lo JC, Mulligan K, et al.: Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001, 15:F11-18.
16. Noor MA, Seneviratne T, Aweeka FT, et al.: Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002, 16:F1-8.
17. Lee GA, Mafong DD, Lo JC, et al.: Ritonavir acutely induces insulin resistance in healthy normal volunteers. Antivir Ther 2005, 10:L6.
18. Noor MA, Parker RA, O'Mara E, et al.: The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004, 18:2137-2144.
19. Noor MA, Flint OP, Maa JF, Parker RA: Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006, 20:1813-1821.
20. Lee GA, Lo JC, Aweeka F, et al.: Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis 2006, 43:658-660.
21. Lee GA, Seneviratne T, Noor MA, et al.: The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004, 18:641-649.
22. Haugaard SB, Andersen O, Madsbad S, et al.: Skeletal muscle insulin signaling defects downstream of phosphatidylinositol 3-kinase at the level of Akt are associated with impaired non-oxidative glucose disposal in HIV lipodystrophy. Diabetes 2005, 54:3474-3483.
23. Lee G, Rao A, Schwarz JM, et al.: A singe dose of amprenavir does not induce insulin resistance in healthy normal volun-teers. Paper presented at the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin, Ireland; November 13-17, 2005.
24. van der Valk M, Bisschop PH, Romijn JA, et al.: Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 2001, 15:2093-2100.
25. Grunfeld C, Kotler DP, Hamadeh R, et al.: Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989, 86:27-31.
26. Feingold KR, Krauss RM, Pang M, et al.: The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 1993, 76:1423-1427.
27. Riddler SA, Smit E, Cole SR, et al.: Impact of HIV infection and HAART on serum lipids in men. JAMA 2003, 289:2978-2982.
28. Purnell JQ, Zambon A, Knopp RH, et al.: Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. Aids. 2000; 14(1):51-57.
29. Lee GA, Rao MN, Grunfeld C: The effects of HIV protease inhibitors on carbohydrate and lipid metabolism. Curr HIV/AIDS Rep 2005, 2:39-50.
30. Jemsek JG, Arathoon E, Arlotti M, et al.: Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis 2006, 42:273-280.
31. Unger RH: Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003, 144:5159-5165.
32. He Q, Engelson ES, Kotler DP: A comparison of abdominal subcutaneous adipose tissue pattern in obese and lean HIV-infected women. J Nutr 2005, 135:53-57.
33. Bacchetti P, Gripshover B, Grunfeld C, et al.: Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005, 40:121-131.
34. Wand H, Law MG, Emery S, et al.: Increase in limb fat after nucleoside analogue cessation is not associated with decreased visceral fat and has different risk factors. Paper presented at the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin, Ireland; November 13-17, 2005.
35. Haerter G, Manfras BJ, Mueller M, et al.: egression of lipodystrophy in HIV-infected patients under therapy with the new protease inhibitor atazanavir. AIDS 2004, 18:952-955.
36. Arranz Caso JA, Lopez JC, Santos I, et al.: A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load. HIV Med 2005, 6:353-359.
37. McComsey GA, Ward DJ, Hessenthaler SM, et al.: Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004, 38:263-270.
38. Shlay JC, Visnegarwala F, Bartsch G, et al.: Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr 2005, 38:147-155.
39. Walli R, Herfort O, Michl GM, et al.: Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998, 12:F167-173.
40. Dube MP, Johnson DL, Currier JS, Leedom JM: Protease inhibitor-associated hyperglycaemia. Lancet 1997, 350:713-714.
41. Behrens G, Dejam A, Schmidt H, et al.: Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999, 13:F63-70.
42. Hruz PW, Murata H, Qiu H, Mueckler M: Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes 2002, 51:937-942.
43. Hertel J, Struthers H, Horj CB, Hruz PW: A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity. J Biol Chem 2004, 279:55147-55152.
44. Rudich A, Ben-Romano R, Etzion S, Bashan N: Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors. Acta Physiol Scand 2005, 183:75-88.
45. Schutt M, Meier M, Meyer M, et al.: The HIV-1 protease inhibitor indinavir impairs insulin signaling in HepG2 hepatoma cells. Diabetologia 2000, 43:1145-1148.
46. Cammalleri C, Germinario RJ: The effects of protease inhibitors on basal and insulin-stimulated lipid metabolism, insulin binding, and signaling. J Lipid Res 2003, 44:103-108.
47. Caron M, Auclair M, Vigouroux C, et al.: The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001, 50:1378-1388.
48. Xu A, Yin S, Wong L, et al.: Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology 2004, 145:487-494.
49. Murata H, Hruz PW, Mueckler M: The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000, 275:20251-20254.
50. Murata H, Hruz PW, Mueckler M: Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 2002, 16:859-863.
51. Yan Q, Hruz PW: Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal. J Acquir Immune Defic Syndr 2005, 40:398-403.
52. Woerle HJ, Mariuz PR, Meyer C, et al.: Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 2003, 52:918-925.
53. Koster JC, Remedi MS, Qiu H, et al.: HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes 2003, 52:1695-1700.
54. Flint OP, Lubinski J, Parker RA, Noor MA: Comparative effects of atazanavir versus other HIV protease inhibitors on glucose and amino acid stimulated insulin secretion. Paper presented at the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin, Ireland; November 13-17, 2005.
55. Dufer M, Neye Y, Krippeit-Drews P, Drews G: Direct interference of HIV protease inhibitors with pancreatic beta-cell function. Naunyn Schmiedebergs Arch Pharmacol 2004, 369:583-590.
56. Dubois M, Kerr-Conte J, Gmyr V, et al.: Non-esterified fatty acids are deleterious for human pancreatic islet function at physiological glucose concentration. Diabetologia 2004, 47:463-469.
57. Shahmanesh M, Das S, Stolinski M, et al.: Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodeficiency virus-infected patients with mild dyslipidemia. J Clin Endocrinol Metab 2005, 90:755-760.
58. Sekhar RV, Jahoor F, Pownall HJ, et al.: Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolemia in HIV lipodystrophy syndrome. Am J Clin Nutr 2005, 81:1405-1410.
59. Riddle TM, Kuhel DG, Woollen LA, et al.: HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001, 276:37514-37519.
60. Horton JD, Goldstein JL, Brown MS: SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002, 109:1125-1131.
61. Hirano Y, Yoshida M, Shimizu M, Sato R: Direct demonstration of rapid degradation of nuclear sterol regulatory element-binding proteins by the ubiquitin-proteasome pathway. J Biol Chem 2001, 276:36431- 36437.
62. Williams K, Rao YP, Natarajan R, et al.: Indinavir alters sterol and fatty acid homeostatic mechanisms in primary rat hepatocytes by increasing levels of activated sterol regulatory element-binding proteins and decreasing cholesterol 7alpha-hydroxylase mRNA levels. Biochem Pharmacol 2004, 67:255-267.
63. Caron M, Auclair M, Sterlingot H, et al.: Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS 2003, 17:2437-2444.
64. Zhang K, Kaufman RJ: Signaling the unfolded protein response from the endoplasmic reticulum. J Biol Chem 2004, 279:25935-25938.
65. Xu C, Bailly-Maitre B, Reed JC: Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 2005, 115:2656-2664.
66. Travers KJ, Patil CK, Wodicka L, et al.: Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated degrada-tion. Cell 2000, 101:249-258.
67. Kaufman RJ, Scheuner D, Schroder M, et al.: The unfolded protein response in nutrient sensing and differentiation. Nat Rev Mol Cell Biol 2002, 3:411-421.
68. Liang JS, Distler O, Cooper DA, et al.: HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001, 7:1327-1331.
69. Nawaz Z, O'Malley BW: Urban renewal in the nucleus: is protein turnover by proteasomes absolutely required for nuclear receptor-regulated transcription? Mol Endocrinol 2004, 18:493-499.
70. Schmidtke G, Holzhutter HG, Bogyo M, et al.: How an inhibitor of the HIV-I protease modulates proteasome activity. J Biol Chem 1999, 274:35734-35740.
71. Pajonk F, Himmelsbach J, Riess K, et al.: The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 2002, 62:5230-5235.
72. Parker RA, Flint OP, Mulvey R, et al.: Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Mol Pharmacol 2005, 67:1909-1919.
73. Summers SA, Nelson DH: A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing's syndrome. Diabetes 2005, 54:591-602.
74. Shikuma CM, Day LJ, Gerschenson M: Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction. Curr Drug Targets Infect Disord 2005, 5:255-262.
75. Nolte LA, Yarasheski KE, Kawanaka K, et al.: The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle. Diabetes 2001, 50:1397-1401.
76. Reeds DN, Cade WT, Patterson BW, et al.: Whole-body proteolysis rate is elevated in HIV-associated insulin resistance. Diabetes 2006, 55:2849-2855.
77. Reeds DN, Yarasheski KE, Fontana L, et al.: Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia. Am J Physiol Endocrinol Metab 2006, 290:E47-53.
78. Pinti M, Salomoni P, Cossarizza A: Anti-HIV drugs and the mitochondria. Biochim Biophys Acta 2006, 1757:700-707.
79. Straczkowski M, Kowalska I, Nikolajuk A, et al.: Relationship between insulin sensitivity and sphingomyelin signaling pathway in human skeletal muscle. Diabetes 2004, 53:1215-1221.
80. Hadigan C, Kamin D, Liebau J, et al.: Depot specific regulation of glucose uptake and insulin sensitivity in HIV-lipodystrophy. Am J Physiol Endocrinol Metab 2005, 30:30. Physiologic link between glucose uptake and body fat redistribution.
81. Staiger H, Tschritter O, Machann J, et al.: Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Obes Res 2003, 11:368-372.
82. Berg AH, Combs TP, Du X, et al.: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001, 7:947-953.
83. Vigouroux C, Maachi M, Nguyen TH, et al.: Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003, 17:1503-1511.
84. Weyer C, Funahashi T, Tanaka S, et al.: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935.